|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Shaheed Faghihi Hospital |
|---|---|
| Collaborator: |
Shiraz University of Medical Sciences |
| Information provided by: | Shaheed Faghihi Hospital |
| ClinicalTrials.gov Identifier: | NCT01015937 |
Purpose
The purpose of this study is to investigate whether turmeric is effective in improvement of diabetic nephropathy and in decrease in the amount of proteinuria and cytokine levels.
| Condition | Intervention |
|---|---|
|
Diabetic Nephropathy Proteinuria |
Drug: Turmeric extract Drug: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Enrollment: | 50 |
| Study Start Date: | March 2008 |
| Study Completion Date: | August 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Turmeric
diabetic nephropathy patient more than 300 mg/proteinuria |
Drug: Turmeric extract
turmeric 500 mg TID for 45 days
Other Name: turmeric
|
|
Active Comparator: ACE inhibitor + ATI blocker
diabetic nephropathy more than 300 mg/day proteinuria |
Drug: Turmeric extract
turmeric 500 mg TID for 45 days
Other Name: turmeric
Drug: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
maximum dosage as patient tolerated for 45 days
Other Names:
|
Diabetic nephropathy is leading cause of ESRF that many therapy recommended for it. In this study, we investigate effect of turmeric on diabetic nephropathy, thus we selected diabetic nephropathy patients and divided them into 2 groups. One group received turmeric + ACE inhibitor + Angiotensin II receptor blocker (ARB) and the second group received only ACE inhibitor + ARB.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Iran, Islamic Republic of | |
| Clinic | |
| Shiraz, Fars, Iran, Islamic Republic of, 098 | |
| Principal Investigator: | maryam pakfetrat, assistant professor | Shiraz nephro-urology research center |
More Information
| Responsible Party: | Office of Vice Chancellor for research in Shiraz UMS, Shiraz University of Medical Science |
| ClinicalTrials.gov Identifier: | NCT01015937 History of Changes |
| Other Study ID Numbers: | 3997 |
| Study First Received: | November 16, 2009 |
| Last Updated: | November 17, 2009 |
| Health Authority: | Iran: Ministry of Health |
|
diabetes nephropathy turmeric serum IL8 |
serum TGFb serumINF urinary IL8 urine TGFb |
|
Diabetic Nephropathies Kidney Diseases Proteinuria Urologic Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Urination Disorders Urological Manifestations Signs and Symptoms Angiotensin II Angiotensin-Converting Enzyme Inhibitors |
Turmeric extract Vasoconstrictor Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antioxidants Protective Agents Physiological Effects of Drugs |
